Bulletin
Investor Alert

New York Markets After Hours

press release

Nov. 2, 2021, 9:01 a.m. EDT

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") /zigman2/quotes/219511930/composite ALXO -2.00% a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences.

Credit Suisse 30 [th] Annual Healthcare Conference
Format: Fireside chat with analyst, Tiago Fauth
Date: Monday, November 8
Time: 2:40 PM Eastern Time
Webcast link: Available here

Stifel 2021 Healthcare Conference
Format: Fireside chat with analyst, Bradley Canino
Date: Tuesday, November 16
Time: 10:00 AM Eastern Time
Webcast link: Available here

Jefferies 2021 London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee
Date: Thursday, November 18 - Friday, November 19
Webcast link: Available here

Piper Sandler 33 [r] [d ] Virtual Healthcare Conference
Format: Fireside chat with analyst, Christopher Raymond
Date: Monday, November 22
Time: 10:00 AM Eastern Time
Webcast link: Will be made available shortly

A webcast of the fireside chats can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the fireside chat dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpacept (also known as ALX148), is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignances, including acute myeloid leukemia and myelodysplastic syndromes.







        Investor Contact:
        
        Peter Garcia
        Chief Financial Officer, ALX Oncology
        (650) 466-7125 Ext. 113
        peter@alxoncology.com
        
        Argot Partners
        (212)-600-1902
        alxoncology@argotpartners.com
        
        Media Contact:
        
        Karen Sharma
        MacDougall
        (781) 235-3060
        alx@macbiocom.com
        


COMTEX_396227239/2471/2021-11-02T09:00:31

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/219511930/composite
US : U.S.: Nasdaq
$ 15.71
-0.32 -2.00%
Volume: 385,890
Jan. 25, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$649.21 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.